Iafrate: Potent, and hard to find. FGFR fusions, import. to cholangiocarcinomas. '13 https://t.co/OcNNpoimBI #AMP2017

3:34pm November 17th 2017 via Hootsuite

Iafrate: RET+ pts are older, non or light smokers, see resp to Vandetanib. NTRK: rare, about 0.5%, but impt #AMP2017

3:32pm November 17th 2017 via Hootsuite

Iafrate: #AMP2017 '13 ref https://t.co/jiJ5v588vy on RET: 2-3% in NSCLC, 5' end has hi-exp, auto-dimerization domain

3:29pm November 17th 2017 via Hootsuite

Iafrate: #AMP2017 Clin char of ROS1-rearr NSCLC 1% prevalence - amazing crizotinib resp. PFS 20 mos vs 10 mos https://t.co/30J7mCokU1

3:28pm November 17th 2017 via Hootsuite

Iafrate: #AMP2017 '17 NEJM ref for Criz vs Alec https://t.co/yiJeIL3syb

3:26pm November 17th 2017 via Hootsuite

Iafrate: PFS of Alectinib shown better than crizotinib. Criz may not penetrate CNS, while Alectinib may. Recent 1st line approval #AMP2017

3:25pm November 17th 2017 via Hootsuite

Iafrate: 2nd gen inhibitors - Alectinib for those who fail crizotinib, resp rate as good as criz first-line. #AMP2017

3:24pm November 17th 2017 via Hootsuite

Iafrate: Pts that don't respond - minority - 'were they false positives?' #AMP2017

3:23pm November 17th 2017 via Hootsuite

Iafrate: ALK-FISH 'became std of care after the first case'. #AMP2017

3:23pm November 17th 2017 via Hootsuite

Iafrate: Shows data from 1K cases - many singletons. Onto Crizotinib, '07 discovery ref https://t.co/hWlDMtv0ya AMP2017

3:22pm November 17th 2017 via Hootsuite

Iafrate: 50 genes currently. RNA rearr are drivers in ~10% of assay samples. Of these: 15% are novel #AMP2017

3:20pm November 17th 2017 via Hootsuite

Iafrate: Has to be in-frame for fusion det, other criteria. Several hundred to thousands of targets. #AMP2017

3:19pm November 17th 2017 via Hootsuite

Iafrate: #AMP2017 Reviews anchored multiplex tech '14 Nature Med ref https://t.co/d1rJEuTiFh

3:19pm November 17th 2017 via Hootsuite

Iafrate: Shows ALK fig from '10 https://t.co/jqP2SFbR8m with a small but real risk of FN via FISH #AMP2017

3:18pm November 17th 2017 via Hootsuite

Iafrate: Now totally different, about 20 fusions that are actionable. Prevalence listed: many <1%, others 3-5%. #AMP2017

3:15pm November 17th 2017 via Hootsuite

Iafrate: Bluprint Med '14 https://t.co/JcIqO0vgWl chart mining TCGA data. 5y ago were only 3 gene fusions #AMP2017

3:14pm November 17th 2017 via Hootsuite

Iafrate: Showed figure from '11 STM paper https://t.co/Kazpx2UVR9 and relapse. And shows mut freq in common cancers #AMP2017

3:12pm November 17th 2017 via Hootsuite

Iafrate: Shows list of CDx for in NSCLC - total of 5 mutations targets (EGFR, EGFR T790M, ALK, ROS1, PD-1). #AMP2017

3:11pm November 17th 2017 via Hootsuite

Iafrate: Showed 'small labs can get the same results'. Shows slide of list of TCGA top 30 mut's in lung ca #AMP2017

3:08pm November 17th 2017 via Hootsuite

Iafrate: >6K biopsies tested to date; 15d TAT; only 18% 'matched', a good first-step. Rare genotype arms 'a big challenge' #AMP2017

3:07pm November 17th 2017 via Hootsuite

Iafrate: To prove clin utility of large panels not done yet. NCI-MATCH: 30 Ph 2 trials as one umbrella. 4 CLIA #AMP2017

3:06pm November 17th 2017 via Hootsuite

Iafrate: "There's a tidal wave of cell-free approaches'. Little performance testing; who will pay the big Q #AMP2017

3:05pm November 17th 2017 via Hootsuite

Iafrate: Commercial labs are numerous - small panels to exomes; academic labs are largely subsidized. #AMP2017

3:05pm November 17th 2017 via Hootsuite

Iafrate: Background: rapid movement of NGS into molecular labs; commercial kits few FDA approved all <5 genes #AMP2017

3:04pm November 17th 2017 via Hootsuite

A. John Iafrate (Mass Gen Hosp Boston MA) Solid Tumor Genotyping: Technical and Clinical Validation with a Focus on Fusions #AMP2017

3:03pm November 17th 2017 via Hootsuite

Nolte: Concludes with ASM POCT rpt "Changing diagnostic paradigms for microbiology" https://t.co/pvXS0FNpRX #AMP2017

10:58am November 17th 2017 via Hootsuite

Nolte: One of their collection loc's: 50% of samples had pertussis. Visited, contamination at point of coll #AMP2017

10:48am November 17th 2017 via Hootsuite

Nolte: POCT operators not familiar with NAATs. Glove changes? Bleach? Pseudo-outbreaks of pertussis from FPs NATs #AMP2017

10:47am November 17th 2017 via Hootsuite

Nolte: Shows real-life desk. Crowded. Buckets, biohazard cans, janitor broom. What could go wrong? #AMP2017

10:47am November 17th 2017 via Hootsuite

Nolte: They use GenMark FilmArray, 7200 tests, $900K annual cost. Discusses 'point of service' vs 'care' options #AMP2017

10:46am November 17th 2017 via Hootsuite

Nolte: Est cost savings of $200/case. Ped pts with GenMark '17 ref survey https://t.co/fkgq0VaA7J 64% considered mgmt change #AMP2017

10:43am November 17th 2017 via Hootsuite

Nolte: Emer Dept pts, 289 Liat tested. Hansen of Univ Minn: documented changes in mgmt in 67% of cases #AMP2017

10:41am November 17th 2017 via Hootsuite

Nolte: No fee-for-service in many loc's (cost vs reimb). Silo'd budgets, no robust clin outcome or health-care econ. data #AMP2017

10:39am November 17th 2017 via Hootsuite

Nolte: "Is the juice worth the squeeze?" Sens inc 20%. May divert up to 20% of in-lab comprehensive resp panel orders #AMP2017

10:38am November 17th 2017 via Hootsuite

Nolte: Reimb $115.92 for A/B, $174.76 A/B&RSV, $47.80 GAS. 410% incr in costs. #AMP2017

10:37am November 17th 2017 via Hootsuite

Nolte: $120K for old tests. For Liat: same volumes, INF A/B cost $37.87, A/B & RSV $45.88; GAS $23.87 #AMP2017

10:36am November 17th 2017 via Hootsuite

Nolte: Cost and reimb for RADTs: they did 7,790 tests for inf A/B, $98,031 at $16.33. Cost was $12.30 #AMP2017

10:35am November 17th 2017 via Hootsuite

Nolte: Showed fig Ct values by Liat, cp to Alere. Late Cts were Alere FN. #AMP2017

10:34am November 17th 2017 via Hootsuite

Nolte: Liat is ampl plot, no Ct data. Roche permission 'had to be signed by the Pope I think' (!!) #AMP2017

10:33am November 17th 2017 via Hootsuite

Nolte: But Alere was 73%; FilmArray RP was the comparator. Alere reported by others higher #AMP2017

10:33am November 17th 2017 via Hootsuite

Nolte: Liat: 300uL sample, scan, load. Published '16 side-by-side https://t.co/OPeJLawJA7 Liat performed 100% #AMP2017

10:32am November 17th 2017 via Hootsuite

Nolte: Ease of Alere: many moving parts, 7 steps, 3 min warm-up req'd (not ideal). Liat: simpler #AMP2017

10:31am November 17th 2017 via Hootsuite

Nolte: Onto BioFire Syndromic Panel POCT: 14 viruses, 3 bact, 2 min ho time, 1h analysis #AMP2017

10:30am November 17th 2017 via Hootsuite

Nolte: Alere RALS is agnostic; Liat is HL7 (more trad) #AMP2017

10:29am November 17th 2017 via Hootsuite

Nolte: Both qual results, both nasal swabs, 15m vs 20m time. Alere has sped up to 5 min in newer version #AMP2017

10:28am November 17th 2017 via Hootsuite

Nolte: Shows Alere i cp to Liat: NEAR, mol beacons vs real-time PCR, Taqman. NEAR = nicking isothermal ampl #AMP2017

10:27am November 17th 2017 via Hootsuite

Nolte: Adv for NAATs for infl: no confirm test needed; inc sens dec potential of timing, pt pop, source, collection issues #AMP2017

10:26am November 17th 2017 via Hootsuite

Nolte: iStat is $5-$8, if operator error is high then the costs add up. Connectivity to EMR w/ NAAT 'is a big deal' #AMP2017

10:25am November 17th 2017 via Hootsuite

Nolte: Moderate throughput for NAAT; trad immunoassay are prone to operator error. Less for digital immno; unk for NAAT #AMP2017

10:23am November 17th 2017 via Hootsuite

Nolte: For lateral flow, about 54% sens (var), digital immuno 80%, NAAT 95%. Reimb from $16.33 (Medicare) to NA $115.92 #AMP2017

10:22am November 17th 2017 via Hootsuite